Rangaswamy Govindarajan MD

Oncology•Little Rock, AR

Professor, Internal Medicine, University of Arkansas COM

Join to View Full Profile

4301 W Markham St# 783Little Rock, AR 72205
Phone+1 501-686-8000

Summary

Dr. Rangaswamy Govindarajan is an oncologist in Little Rock, AR and is affiliated with multiple hospitals in the area, including John L. McClellan Memorial Veterans Hospital, Ashley County Medical Center, and UAMS Medical Center. He received his medical degree from Mysore Medical College and has been in practice 37 years. He specializes in hematologic oncology.

Education & Training

University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 1993 - 1996
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1992 - 1993
Mysore Medical CollegeClass of 1980

Certifications & Licensure

AR State Medical License 1993 - 2026
FL State Medical License 2002 - 2005

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma Start of enrollment: 2006 Feb 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients With Colon Cancer Start of enrollment: 2011 Nov 01
Completed
Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth Start of enrollment: 2012 Aug 01
Terminated
Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
ACTIVE_NOT_RECRUITING
PHASE3
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors.
Young Kwang Chae, Megan Othus, Sandip Patel, Benjamin Powers, Chung-Tsen Hsueh
Journal for Immunotherapy of Cancer. 2024-09-28
6 citations
Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation.
Cathy Eng, Emerson Y. Chen, Jane E. Rogers, Mark A. Lewis, Jonathan R. Strosberg
JCO Oncology Practice. 2021-02-03
78 citations
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert
Nature Medicine. 2020-10-05

Press Mentions

New UAMS Baptist Health Cancer Center Opens in North Little RockAugust 30th, 2021

Professional Memberships

American Society of Clinical Oncology - ASCO
Member